Biotech | March 10, 2022
Gufic Biosciences collaborates with Selvax for cancer treatment
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumour boards, clinical trials, synoptic reporting, quantitative analytics, and AI
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
The surgery was helmed by Prof. Dr. Vishwanath Pai, Sr. Consultant, Department of Minimally Invasive Surgery, Prashanth Hospitals, Velachery
Whipple procedure is a very complex operation, mainly performed to remove pancreatic cancer
Subscribe To Our Newsletter & Stay Updated
